Shinji Mii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Shinji Mii has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Akina Oishi
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Atsushi Enomoto
Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, 466-8550, Japan
1 shared publication - Eri Ishikawa
Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Goro Nakayama
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Haruhiko Suzuki
Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan
1 shared publication - Hiroki Kawashima
Department of Gastroenterology and Hepatology Nagoya University Graduate School of Medicine Nagoya Aichi Japan
1 shared publication
Latest Publications
- Open Access
- 19 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (13)
Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease
Dysfunctional intestinal fibrosis is an irreversible complication of Crohn’s disease (CD), The complex heterogeneity of intestinal mesenchymal cells makes it difficult to understand the pathogenesis of intestinal fibrosis. Previously, we identified Meflin as a marker of fibroblast subsets. This study aimed to explore the role of Meflin-positive fibroblasts in intestinal fibrogenesis and investigate the potential of pharmacological control of Meflin expression as a treatment for patients with CD. Our results indicated that Meflin expression was upregulated in fibroblasts at the early stage of fibrosis but was downregulated in established fibrosis in both patients with CD and two different mouse models, which are the chronic dextran sodium sulfate (DSS) model and an interleukin-10-deficient model that spontaneously develops intestinal inflammation. Meflin-deficient mice exacerbated intestinal fibrosis with dysregulated expression of non-canonical Wnt ligand WNT5A and its receptor ROR2. Pharmacologically induced Meflin expression through the administration of a synthetic retinoid reversed intestinal fibrosis in the DSS model and suppressed pro-fibrotic protein secretion in fibroblasts isolated from patients with CD. Our findings indicate that Meflin-positive fibroblasts represent a functional subpopulation that suppresses intestinal fibrosis. Augmentation of Meflin expression shows antifibrotic effects and holds promise as a therapeutic approach for intestinal fibrosis in patients with CD.
- 19 May 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (13)
Open AccessMeflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease
Dysfunctional intestinal fibrosis is an irreversible complication of Crohn’s disease (CD), The complex heterogeneity of intestinal mesenchymal cells makes it difficult to understand the pathogenesis of intestinal fibrosis. Previously, we identified Meflin as a marker of fibroblast subsets. This study aimed to explore the role of Meflin-positive fibroblasts in intestinal fibrogenesis and investigate the potential of pharmacological control of Meflin expression as a treatment for patients with CD. Our results indicated that Meflin expression was upregulated in fibroblasts at the early stage of fibrosis but was downregulated in established fibrosis in both patients with CD and two different mouse models, which are the chronic dextran sodium sulfate (DSS) model and an interleukin-10-deficient model that spontaneously develops intestinal inflammation. Meflin-deficient mice exacerbated intestinal fibrosis with dysregulated expression of non-canonical Wnt ligand WNT5A and its receptor ROR2. Pharmacologically induced Meflin expression through the administration of a synthetic retinoid reversed intestinal fibrosis in the DSS model and suppressed pro-fibrotic protein secretion in fibroblasts isolated from patients with CD. Our findings indicate that Meflin-positive fibroblasts represent a functional subpopulation that suppresses intestinal fibrosis. Augmentation of Meflin expression shows antifibrotic effects and holds promise as a therapeutic approach for intestinal fibrosis in patients with CD.